Spyre Therapeutics(SYRE)
$97.63-3.83 (-3.77%)
SYRE
Spyre Therapeutics ownership
$97.63
At close:-3.83 (-3.77%)
Want to see SYRE full AI Analyst Report?
Spyre Therapeutics (SYRE) Ownership - Who Owns Spyre Therapeutics?
586 Followers
Spyre Therapeutics (SYRE) Ownership Overview
- 1.61% Insiders
- 28.58% Mutual Funds
- 51.03% Other Institutional Investors
- 15.81% ETFs
- 2.97% Public Companies and Individual Investors
The ownership structure of Spyre Therapeutics (SYRE) stock is a mix of institutional, retail, and individual investors. Approximately 95.42% of the company’s stock is owned by Institutional Investors, 1.61% is owned by Insiders, and 2.97% is owned by Public Companies and Individual Investors.
Institutional holdings as of
The ownership structure of Spyre Therapeutics (SYRE) stock is a mix of institutional, retail, and individual investors. Approximately 95.42% of the company’s stock is owned by Institutional Investors, 1.61% is owned by Insiders, and 2.97% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
| Date | Name | Activity | Value |
|---|---|---|---|
| Oct 01, 2026 | Scott L Burrows | $1,573,075 | |
| Jun 25, 2026 | Scott L Burrows | $1,307,000 | |
| Jun 22, 2026 | Fairmount Funds Management Llc | $399,658,667 |
Recent Hedge Fund Trading Activity
| Date | Firm | Activity | Value |
|---|---|---|---|
| Sep 30, 2026 | Perceptive Advisors Llc | $292,102,355 | |
| Sep 30, 2026 | Driehaus Capital Management Llc | $245,762,685 | |
| Sep 30, 2026 | Blackstone Inc. | $15,675,423 | |
| Sep 30, 2026 | Woodline Partners Lp | $25,541,906 |
Top Shareholders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Vanguard | 7,003,135 | Institution | 7.37% | 683,716,070 |
| BlackRock, Inc. | 6,779,486 | Institution | 7.14% | 661,881,218 |
| Vanguard Index Funds | 4,832,758 | Institution | 5.09% | 471,822,164 |
| Fidelity Mt. Vernon Street Trust | 4,276,963 | Institution | 4.50% | 417,559,898 |
| Peter Harwin | 4,018,101 | Institution | 4.23% | 392,287,201 |
| Ishares | 3,809,132 | Institution | 4.01% | 371,885,557 |
| Joseph Edelman | 3,280,943 | Institution | 3.45% | 320,318,465 |
| Smallcap World Fund Inc | 2,780,536 | Institution | 2.93% | 271,463,730 |
| Steve Weber | 2,760,448 | Institution | 2.91% | 269,502,538 |
| Spdr | 2,008,864 | Institution | 2.12% | 196,125,392 |
Top Mutual Fund Holders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Vanguard Index Funds | 4,832,758 | Institution | 5.09% | 471,822,164 |
| Fidelity Mt. Vernon Street Trust | 4,276,963 | Institution | 4.50% | 417,559,898 |
| Smallcap World Fund Inc | 2,780,536 | Institution | 2.93% | 271,463,730 |
| Fidelity Securities Fund | 1,592,057 | Institution | 1.68% | 155,432,525 |
| Fidelity Advisor Series Vii | 1,197,347 | Institution | 1.26% | 116,896,988 |
| Fidelity Salem Street Trust | 1,104,333 | Institution | 1.16% | 107,816,031 |
| Fidelity Select Portfolios | 1,090,057 | Institution | 1.15% | 106,422,265 |
| Fidelity Concord Street Trust | 825,799 | Institution | 0.87% | 80,622,756 |
| T. Rowe Price Health Sciences Fund, Inc. | 711,845 | Institution | 0.75% | 69,497,427 |
| T. Rowe Price New Horizons Fund, Inc. | 673,799 | Institution | 0.71% | 65,782,996 |
Top ETF Holders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Vanguard Total Stock Market ETF, VTI ETF | 2,106,590 | Institution | 2.22% | 203,412,330 |
| iShares Russell 2000 ETF, IWM ETF | 1,992,748 | Institution | 2.10% | 194,551,987 |
| Vanguard Small-Cap ETF, VB ETF | 1,878,002 | Institution | 1.98% | 181,339,873 |
| SPDR S&P BIOTECH ETF, XBI ETF | 1,751,926 | Institution | 1.84% | 177,750,412 |
| Vanguard Small Cap Value ETF, VBR ETF | 1,220,725 | Institution | 1.29% | 117,873,206 |
| Vanguard Extended Market ETF, VXF ETF | 940,056 | Institution | 0.99% | 90,771,807 |
| iShares Russell 2000 Growth ETF, IWO ETF | 721,491 | Institution | 0.76% | 70,439,166 |
| iShares Biotechnology ETF, IBB ETF | 617,696 | Institution | 0.65% | 60,305,660 |
| Vanguard Russell 2000 ETF, VTWO ETF | 449,552 | Institution | 0.47% | 43,408,741 |
| Schwab U.S. Small-Cap ETF, SCHA ETF | 442,493 | Institution | 0.47% | 44,895,340 |
FAQ
Who Owns Spyre Therapeutics (SYRE)?
According to the latest TipRanks data (13F holdings as of September 30, 2026), approximately 95.42% of the company's stock is held by institutional investors, 1.61% is held by insiders, and 2.97% is held by public companies and individual investors.
What percentage of Spyre Therapeutics (SYRE) stock is held by institutional investors?
According to the latest TipRanks data (13F holdings as of September 30, 2026), approximately 95.42% of Spyre Therapeutics (SYRE) stock is held by institutional investors: 28.58% by mutual funds, 15.81% by ETFs and 51.03% by other institutional investors.
What percentage of Spyre Therapeutics (SYRE) stock is held by retail investors?
According to the latest TipRanks data (13F holdings as of September 30, 2026), approximately 2.97% of Spyre Therapeutics (SYRE) stock is held by public companies and individual investors.
Who owns the most shares of Spyre Therapeutics (SYRE)?
Vanguard owns the most shares of Spyre Therapeutics (SYRE).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.

